311 related articles for article (PubMed ID: 8626361)
1. The safety profile of nefazodone.
Robinson DS; Roberts DL; Smith JM; Stringfellow JC; Kaplita SB; Seminara JA; Marcus RN
J Clin Psychiatry; 1996; 57 Suppl 2():31-8. PubMed ID: 8626361
[TBL] [Abstract][Full Text] [Related]
2. Tolerability and safety: essentials in antidepressant pharmacotherapy.
Lader MH
J Clin Psychiatry; 1996; 57 Suppl 2():39-44. PubMed ID: 8626362
[TBL] [Abstract][Full Text] [Related]
3. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine.
Owen JR; Nemeroff CB
Depress Anxiety; 1998; 7 Suppl 1():24-32. PubMed ID: 9597349
[TBL] [Abstract][Full Text] [Related]
4. Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression.
Cohn CK; Robinson DS; Roberts DL; Schwiderski UE; O'Brien K; Ieni JR
J Clin Psychiatry; 1996; 57 Suppl 2():15-8. PubMed ID: 8626358
[TBL] [Abstract][Full Text] [Related]
5. Nefazodone: aspects of efficacy.
Rickels K; Robinson DS; Schweizer E; Marcus RN; Roberts DL
J Clin Psychiatry; 1995; 56 Suppl 6():43-6. PubMed ID: 7649973
[TBL] [Abstract][Full Text] [Related]
6. [Fluoxetine and tricyclic antidepressants: clinical tolerance in short-term combined administration].
Bonin B; Bertschy G; Baumann P; Francois T; Vandel P; Vandel S; Sechter D; Bizouard P
Encephale; 1996; 22(3):221-7. PubMed ID: 8767051
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic dose range of nefazodone in the treatment of major depression.
Robinson DS; Marcus RN; Archibald DG; Hardy SA
J Clin Psychiatry; 1996; 57 Suppl 2():6-9. PubMed ID: 8626365
[TBL] [Abstract][Full Text] [Related]
8. Efficacy in long-term treatment of depression.
Montgomery SA
J Clin Psychiatry; 1996; 57 Suppl 2():24-30. PubMed ID: 8626360
[TBL] [Abstract][Full Text] [Related]
9. Care of the sexually active depressed patient.
Hirschfeld RM
J Clin Psychiatry; 1999; 60 Suppl 17():32-5; discussion 46-8. PubMed ID: 10446740
[TBL] [Abstract][Full Text] [Related]
10. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction.
Montejo AL; Llorca G; Izquierdo JA; Rico-Villademoros F
J Clin Psychiatry; 2001; 62 Suppl 3():10-21. PubMed ID: 11229449
[TBL] [Abstract][Full Text] [Related]
11. The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings.
Zajecka JM
J Clin Psychiatry; 1996; 57 Suppl 2():10-4. PubMed ID: 8626357
[TBL] [Abstract][Full Text] [Related]
12. Nefazodone in the treatment of severe, melancholic, and recurrent depression.
Marcus RN; Mendels J
J Clin Psychiatry; 1996; 57 Suppl 2():19-23. PubMed ID: 8626359
[TBL] [Abstract][Full Text] [Related]
13. A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression.
Feighner JP; Pambakian R; Fowler RC; Boyer WF; D'Amico MF
Psychopharmacol Bull; 1989; 25(2):219-21. PubMed ID: 2690165
[TBL] [Abstract][Full Text] [Related]
14. Nefazodone therapy in patients with treatment-resistant or treatment-intolerant depression and high psychiatric comorbidity.
Sajatovic M; DiGiovanni S; Fuller M; Belton J; DeVega E; Marqua S; Liebling D
Clin Ther; 1999 Apr; 21(4):733-40. PubMed ID: 10363738
[TBL] [Abstract][Full Text] [Related]
15. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials.
Sussman N; Ginsberg DL; Bikoff J
J Clin Psychiatry; 2001 Apr; 62(4):256-60. PubMed ID: 11379839
[TBL] [Abstract][Full Text] [Related]
16. Six-year perspectives on the safety and tolerability of nefazodone.
Dunner DL; Laird LK; Zajecka J; Bailey L; Sussman N; Seabolt JL
J Clin Psychiatry; 2002; 63 Suppl 1():32-41. PubMed ID: 11890563
[No Abstract] [Full Text] [Related]
17. An open-label trial of nefazodone in high comorbidity panic disorder.
DeMartinis NA; Schweizer E; Rickels K
J Clin Psychiatry; 1996 Jun; 57(6):245-8. PubMed ID: 8666561
[TBL] [Abstract][Full Text] [Related]
18. Fluoxetine and concomitant centrally acting medication use during clinical trials of depression: the absence of an effect related to agitation and suicidal behavior.
Wernicke JF; Sayler ME; Koke SC; Pearson DK; Tollefson GD
Depress Anxiety; 1997; 6(1):31-9. PubMed ID: 9394873
[TBL] [Abstract][Full Text] [Related]
19. Management of depression in the elderly.
Williams GO
Prim Care; 1989 Jun; 16(2):451-74. PubMed ID: 2664841
[TBL] [Abstract][Full Text] [Related]
20. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
